Table 5 Mean ADC values in patients evaluated by RECIST 1.1, m RECIST, and tumor volume
RECIST 1.1 | Mean ADC value | m RECIST | Mean ADC value | Tumor volume (VOL) | Mean ADC value |
|---|---|---|---|---|---|
Increased in tumor longest dimension (18/36) | 12/18 (67%) had decrease in mean ADC values | Increased tumor enhancing component (15/36) | 11/15 (73.3%) showed decreased mean ADC values | Increased tumor volume (17/36) | Reduction of mean ADC value in 11/17 (64.7%) |
6/18 (33%) of patients had increase in mean ADC values | 4/15 (26.7%) showed increased mean ADC values | 6/17 (35.3%) increase in the mean ADC value | |||
No change in tumor size (1/36) | Increase in mean ADC value | No change in enhancing tumor size (1/36) | Increased mean ADC value | No change in enhancing tumor volume (1/36) | Increased mean ADC value |
Decrease in tumor longest dimension (17/36) | 16/17 (94%) of patients showed increased mean ADC values | Decreased enhancing tumor sizes (20/36) | 18/20 (90%) of patients showed increase in mean ADC values | Decreased enhancing tumor volume (18/36) | 16/18 (88.8%) showed increase in mean ADC values |
1/17 (6%) showed decreased mean ADC value. | 2/20 (10%) showed decrease in mean ADC values | 2/18(11.2%) showed decrease in mean ADC values |